Jacobs Levy Equity Management, Inc Gilead Sciences, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 508,291 shares of GILD stock, worth $46.4 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

508,291

Previous 968,172 47.5%

Holding current value

$46.4 Million

Previous $66.4 Million 35.86%

% of portfolio

0.17%

Previous 0.29%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $30.6 Million - $38.6 Million	-459,881 Reduced 47.5%	508,291 $42.6 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $28.4 Million - $32.8 Million	450,402 Added 86.99%	968,172 $66.4 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $27.9 Million - $34.1 Million	390,301 Added 306.19%	517,770 $37.9 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $34,583 - $39,218	-472 Reduced 0.37%	127,469 $10.3 Million
Q3 2023 Nov 16, 2023	SELL	$73.94 - $80.67 $4.85 Million - $5.29 Million	-65,536 Reduced 33.87%	127,941 $9.59 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $7.59 Million - $8.65 Million	99,805 Added 106.55%	193,477 $14.9 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $6.13 Million - $6.99 Million	79,342 Added 553.68%	93,672 $7.77 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $58.1 Million - $83.4 Million	-932,656 Reduced 98.49%	14,330 $1.23 Million
Q3 2022 Nov 15, 2022	SELL	$59.54 - $68.01 $85.6 Million - $97.7 Million	-1,437,144 Reduced 60.28%	946,986 $58.4 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $5.09 Million - $5.74 Million	-88,239 Reduced 3.57%	2,384,130 $147 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $28.7 Million - $36 Million	495,476 Added 25.06%	2,472,369 $147 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $26.1 Million - $29.6 Million	401,998 Added 25.53%	1,976,893 $144 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $39.8 Million - $43 Million	-588,194 Reduced 27.19%	1,574,895 $110 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $16.2 Million - $17.7 Million	254,884 Added 13.36%	2,163,089 $149 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $3.76 Million - $4.29 Million	62,701 Added 3.4%	1,908,205 $123 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $26 Million - $29.6 Million	458,871 Added 33.09%	1,845,504 $108 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $678,256 - $852,789	10,922 Added 0.79%	1,386,633 $87.6 Million
Q2 2020 Aug 17, 2020	BUY	$72.34 - $84.0 $5.41 Million - $6.29 Million	74,839 Added 5.75%	1,375,711 $106 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $18.4 Million - $23.6 Million	-294,040 Reduced 18.44%	1,300,872 $97.3 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $29.3 Million - $32.2 Million	474,692 Added 42.37%	1,594,912 $104 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $45.7 Million - $50.5 Million	731,855 Added 188.45%	1,120,220 $71 Million
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $10.8 Million - $12.1 Million	174,475 Added 81.57%	388,365 $26.2 Million
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $11.8 Million - $13.3 Million	189,460 Added 775.52%	213,890 $13.9 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $1.48 Million - $1.93 Million	24,430 New	24,430 $1.53 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $8.75 Million - $10.3 Million	-122,998 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$72.11 - $85.47 $13.7 Million - $16.2 Million	-189,656 Reduced 60.66%	122,998 $9.97 Million
Q2 2017 Nov 09, 2017	BUY	N/A	312,654	312,654 $22.1 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Gilead Sciences, Inc. Transaction History